Verge Genomics is a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery. Verge was born from the convergence of multiple technological forces, including human genomics, machine learning, biological engineering, and translational medicine, that enable us to decipher complex biological and molecular mechanisms. Our CONVERGETM platform harnesses data from human tissue and human-derived model systems, which we believe increases the likelihood of translational success in the clinic, by using patient data to drive discovery and development. Verge built one of the world's largest proprietary multi-omics databases directly from patient tissue, including from over 1,000 patients with neurodegenerative diseases. We use machine learning to map the complex causes of disease and develop those insights into proprietary drug candidates on internal biology and chemistry platforms. Our lead program is a PIKfyve inhibitor for the treatment of ALS and is currently in a Phase 1 clinical trial. It was discovered entirely from our proprietary CONVERGETM platform and brought from research to the clinic in a rapid timeline of only 4 years. Verge is advancing a robust pipeline of programs in Parkinson's Disease, Frontotemporal Dementia, Progressive Supranuclear Palsy, Schizophrenia, and other devastating diseases with no effective treatments to date. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.